Silexion Therapeutics Q2 2025 Earnings Report

Silexion Therapeutics EPS Results

• Actual EPS: -$43.20
• Consensus EPS: -$31.50
• Beat/Miss: Missed by -$11.70
• One Year Ago EPS: N/A

Silexion Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Silexion Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Silexion Therapeutics (NASDAQ:SLXN) Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer. The company has also developed LODER, a localized delivery platform intended to release siRNA directly within a tumor. These programs have primarily been evaluated for pancreatic ductal adenocarcinoma, with the broader goal of addressing KRAS-driven solid tumors.

The company traces its origins to an Israeli biotechnology operation focused on localized RNA-interference therapies and became publicly traded on Nasdaq through a business combination in 2024. Silexion’s activities are primarily focused on research and clinical development, and its drug candidates remain investigational rather than commercially approved products.